JHEP reports : innovation in hepatology · 2025
Blood and tissue dysregulated bile acids and short-chain fatty acids in cholangiocarcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Yaming, Hassan Hind, Brooks Tayla R, VanLith Caitlin, Cooley Matthew, Elgozair Mohamad, Ahmed Fowsiyo Y, Giama Nasra H, Campbell Nellie A, Su Lianyong, Tai Yun-Ling, Ren Jianlin, Zhou Huiping, Roberts Lewis R
Аннотация
BACKGROUND & AIMS: Dysregulated bile acid (BA) homeostasis has been implicated in the initiation and progression of cholangiocarcinoma (CCA). The aim of this study was to investigate the roles of circulating and tumor BAs, oxysterols, short-chain fatty acids (SCFAs), transcriptomic changes, and stool microbiota composition in CCA, and their potential diagnostic and therapeutic implications.
METHODS: We used ultra-performance liquid chromatography-tandem mass spectrometry to quantify BAs, oxysterols, and SCFAs in serum from patients with benign focal nodular hyperplasia (n = 27), primary sclerosing cholangitis (PSC; n = 20), intrahepatic CCA (iCCA; n = 29), and extrahepatic CCA (eCCA; n = 35), and in tumor and adjacent non-tumor iCCA (n = 30) and eCCA (n = 26) tissues. Publicly available liver transcriptome and gut microbiome datasets were analyzed to assess BA metabolic pathway activity and related gene expression profiles.
RESULTS: Total primary conjugated BA levels and the taurine-to-glycine ratio of conjugated BAs were significantly elevated in the serum of patients with PSC and CCA compared to controls with focal nodular hyperplasia (p <0.05). Transcriptomic analysis revealed a significant downregulation of GLYAT and BAAT, key genes involved in glycine and taurine conjugation, in PSC and CCA (p <0.05). Hepatic oxysterol levels were increased concomitantly with BAs in patients with CCA. Among SCFAs, butyric acid was positively correlated with conjugated BAs in the serum of patients with iCCA, whereas acetic acid was negatively correlated with BAs in the serum of patients with non-PSC-eCCA (p <0.05). Conjugated BAs were positively correlated with carbohydrate antigen 19-9 levels in patients with iCCA and non-PSC-eCCA.
CONCLUSIONS: Profound alterations in serum and tissue levels of primary and taurine-conjugated BAs occur during cholangiocarcinogenesis. Further elucidation of the mechanisms regulating BA and oxysterol metabolism in CCA may offer new avenues for diagnosis and therapy.
IMPACT AND IMPLICATIONS: Cholangiocarcinomas (CCAs) are aggressive malignancies with limited therapeutic options. Although CCA cells exhibit distinct metabolic profiles, investigating their regulation through the enterohepatic axis remains challenging. In this study, targeted metabolomics was used to analyze bile acid (BA) profiles in serum and liver tissue, serum short-chain fatty acids, and hepatic oxysterol levels in patients with intrahepatic and extrahepatic CCA, compared to controls with focal nodular hyperplasia and primary sclerosing cholangitis. Liver transcriptome analysis revealed differentially expressed genes involved in BA metabolism in patients with primary sclerosing cholangitis and CCA. Correlations were also examined between BAs, oxysterols, short-chain fatty acids, clinical features, and microbiome components implicated in CCA development. These findings provide new insights into BA dysregulation in CCA and establish a foundation for the development of novel diagnostic biomarkers and therapeutic strategies.
METHODS: We used ultra-performance liquid chromatography-tandem mass spectrometry to quantify BAs, oxysterols, and SCFAs in serum from patients with benign focal nodular hyperplasia (n = 27), primary sclerosing cholangitis (PSC; n = 20), intrahepatic CCA (iCCA; n = 29), and extrahepatic CCA (eCCA; n = 35), and in tumor and adjacent non-tumor iCCA (n = 30) and eCCA (n = 26) tissues. Publicly available liver transcriptome and gut microbiome datasets were analyzed to assess BA metabolic pathway activity and related gene expression profiles.
RESULTS: Total primary conjugated BA levels and the taurine-to-glycine ratio of conjugated BAs were significantly elevated in the serum of patients with PSC and CCA compared to controls with focal nodular hyperplasia (p <0.05). Transcriptomic analysis revealed a significant downregulation of GLYAT and BAAT, key genes involved in glycine and taurine conjugation, in PSC and CCA (p <0.05). Hepatic oxysterol levels were increased concomitantly with BAs in patients with CCA. Among SCFAs, butyric acid was positively correlated with conjugated BAs in the serum of patients with iCCA, whereas acetic acid was negatively correlated with BAs in the serum of patients with non-PSC-eCCA (p <0.05). Conjugated BAs were positively correlated with carbohydrate antigen 19-9 levels in patients with iCCA and non-PSC-eCCA.
CONCLUSIONS: Profound alterations in serum and tissue levels of primary and taurine-conjugated BAs occur during cholangiocarcinogenesis. Further elucidation of the mechanisms regulating BA and oxysterol metabolism in CCA may offer new avenues for diagnosis and therapy.
IMPACT AND IMPLICATIONS: Cholangiocarcinomas (CCAs) are aggressive malignancies with limited therapeutic options. Although CCA cells exhibit distinct metabolic profiles, investigating their regulation through the enterohepatic axis remains challenging. In this study, targeted metabolomics was used to analyze bile acid (BA) profiles in serum and liver tissue, serum short-chain fatty acids, and hepatic oxysterol levels in patients with intrahepatic and extrahepatic CCA, compared to controls with focal nodular hyperplasia and primary sclerosing cholangitis. Liver transcriptome analysis revealed differentially expressed genes involved in BA metabolism in patients with primary sclerosing cholangitis and CCA. Correlations were also examined between BAs, oxysterols, short-chain fatty acids, clinical features, and microbiome components implicated in CCA development. These findings provide new insights into BA dysregulation in CCA and establish a foundation for the development of novel diagnostic biomarkers and therapeutic strategies.